Demo Pharmaceutical Industry

Executive Summary

DEMO Pharmaceutical Industry (DEMO S.A.) is a fully integrated Greek pharmaceutical company specializing in small molecules, medical devices, and nutritional supplements. Founded in 1974 and headquartered in Athens, the company operates one of Southeast Europe’s largest injectable drugs manufacturing plants, exporting 80% of its production to 96 countries. Its broad portfolio and global reach underscore its strong operational foundation and ability to compete in international markets, despite being privately held with limited public disclosure. Looking ahead, DEMO is well-positioned to capitalize on growing demand for generic injectables and niche therapeutic segments. Its established manufacturing capabilities and extensive distribution network provide a solid platform for further geographic expansion and product development. While the company remains private without near-term liquidity events, its consistent export-driven growth and potential for strategic partnerships or facility expansions offer upside. Key risks include regulatory dependence and competition from larger generic players. Overall, DEMO represents a stable but non-catalyst-rich opportunity in the European pharma space.

Upcoming Catalysts (preview)

• Q3 2026Completion of new injectable production line expansion at Athens plant85% success
• Q4 2026Receipt of EU marketing authorization for a high-value generic oncology product60% success